Leigh Brody and Dominik Leisi have joined Albion Capital to work on the life science investment team for UCL Technology Fund.

Unseen Capital is targeting a $100m close for a fund that will invest in healthcare technology developers run by underrepresented founders.

The Oxford-linked oncology drug developer has raised the money from new and existing backers, and will use the cash to boost its product pipeline.

Johnson & Johnson Innovation – JJDC has co-led the computational pathology technology provider's series C round to take its total funding to $195m.

Luba Greenwood has been brought on to run Binney Street Capital on behalf of cancer research and care provider Dana-Farber Cancer Institute.

The stem cell therapy developer has filed to go public seven months after closing $700m in funding from investors including Alphabet unit GV.

The Eli Lilly and Wuxi AppTec-backed oncology drug developer has raised the money from new and existing backers, and will use the cash to boost its product pipeline.

Johnson & Johnson Innovation – JJDC co-led the computational pathology technology provider's series C round to take its total funding to $195m.

Atalanta Therapeutics has launched out of UMass with $110m in combined series A and partnership funding to develop therapies for neurodegenerative diseases.

Three years after launching to commercialise stem cell research from Harvard University, Sana has filed for an initial public offering.